Collegium Pharmaceutical Inc - Asset Resilience Ratio
Collegium Pharmaceutical Inc (COLL) has an Asset Resilience Ratio of 8.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore COLL total asset value for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Collegium Pharmaceutical Inc's Asset Resilience Ratio has changed over time. See how leveraged is Collegium Pharmaceutical Inc's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Collegium Pharmaceutical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Collegium Pharmaceutical Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $135.77 Million | 8.45% |
| Total Liquid Assets | $135.77 Million | 8.45% |
Asset Resilience Insights
- Limited Liquidity: Collegium Pharmaceutical Inc maintains only 8.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Collegium Pharmaceutical Inc Industry Peers by Asset Resilience Ratio
Compare Collegium Pharmaceutical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Collegium Pharmaceutical Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Collegium Pharmaceutical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.54% | $92.20 Million | $1.66 Billion | -0.72pp |
| 2023-12-31 | 6.26% | $71.60 Million | $1.14 Billion | -- |
| 2022-12-31 | 0.00% | $0.00 | $1.17 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $135.57 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $162.02 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $97.72 Million | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more